EHA 2023 | Identifying and managing patients at high risk of developing toxicities following CAR-T therapy
Kai Rejeski, MD, LMU Munich, Munich, Germany, provides insights into the management of toxicities associated with CAR-T therapy including hematological toxicities, cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS). Dr Rejeski emphasizes the need to develop personalized approaches based on a patient’s risk to develop such toxicities, explaining the benefit of using escalated supportive measures and prophylaxis in patients with a high risk of developing CAR-T-associated toxicity. He also explains that patients who experience hematological toxicities should receive a hematopoietic stem cell boost as early as possible if available. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Honoraria; Kite/Gilead: Other: Travel Support, Research Funding
